vs
爱德华生命科学（EW）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
爱德华生命科学的季度营收约是Rollins, Inc.的1.8倍（$1.6B vs $906.4M），爱德华生命科学净利率更高（23.1% vs 11.9%，领先11.2%），爱德华生命科学同比增速更快（16.7% vs 10.2%），过去两年爱德华生命科学的营收复合增速更高（9.7% vs 0.8%）
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
EW vs ROL — 直观对比
营收规模更大
EW
是对方的1.8倍
$906.4M
营收增速更快
EW
高出6.5%
10.2%
净利率更高
EW
高出11.2%
11.9%
两年增速更快
EW
近两年复合增速
0.8%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $906.4M |
| 净利润 | $380.7M | $107.8M |
| 毛利率 | 78.0% | — |
| 营业利润率 | 1.8% | 16.1% |
| 净利率 | 23.1% | 11.9% |
| 营收同比 | 16.7% | 10.2% |
| 净利润同比 | 6.8% | 2.5% |
| 每股收益（稀释后） | $0.66 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EWROL
| Q1 26 | $1.6B | $906.4M | ||
| Q4 25 | $1.6B | $912.9M | ||
| Q3 25 | $1.6B | $1.0B | ||
| Q2 25 | $1.5B | $999.5M | ||
| Q1 25 | $1.4B | $822.5M | ||
| Q4 24 | $1.4B | $832.2M | ||
| Q3 24 | $1.4B | $916.3M | ||
| Q2 24 | $1.4B | $891.9M |
净利润EWROL
| Q1 26 | $380.7M | $107.8M | ||
| Q4 25 | $91.2M | $116.4M | ||
| Q3 25 | $291.1M | $163.5M | ||
| Q2 25 | $333.2M | $141.5M | ||
| Q1 25 | $358.0M | $105.2M | ||
| Q4 24 | $385.6M | $105.7M | ||
| Q3 24 | $3.1B | $136.9M | ||
| Q2 24 | $366.3M | $129.4M |
毛利率EWROL
| Q1 26 | 78.0% | — | ||
| Q4 25 | 78.1% | — | ||
| Q3 25 | 77.8% | — | ||
| Q2 25 | 77.5% | — | ||
| Q1 25 | 78.7% | — | ||
| Q4 24 | 78.9% | — | ||
| Q3 24 | 80.6% | — | ||
| Q2 24 | 79.9% | — |
营业利润率EWROL
| Q1 26 | 1.8% | 16.1% | ||
| Q4 25 | 9.6% | 17.5% | ||
| Q3 25 | 19.8% | 21.9% | ||
| Q2 25 | 26.8% | 19.8% | ||
| Q1 25 | 27.9% | 17.3% | ||
| Q4 24 | 22.6% | 18.1% | ||
| Q3 24 | 25.9% | 20.9% | ||
| Q2 24 | 26.8% | 20.4% |
净利率EWROL
| Q1 26 | 23.1% | 11.9% | ||
| Q4 25 | 5.8% | 12.8% | ||
| Q3 25 | 18.7% | 15.9% | ||
| Q2 25 | 21.7% | 14.2% | ||
| Q1 25 | 25.3% | 12.8% | ||
| Q4 24 | 27.8% | 12.7% | ||
| Q3 24 | 226.7% | 14.9% | ||
| Q2 24 | 26.7% | 14.5% |
每股收益（稀释后）EWROL
| Q1 26 | $0.66 | $0.22 | ||
| Q4 25 | $0.16 | $0.24 | ||
| Q3 25 | $0.50 | $0.34 | ||
| Q2 25 | $0.56 | $0.29 | ||
| Q1 25 | $0.61 | $0.22 | ||
| Q4 24 | $0.65 | $0.22 | ||
| Q3 24 | $5.13 | $0.28 | ||
| Q2 24 | $0.61 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $116.5M |
| 总债务越低越好 | — | $650.6M |
| 股东权益账面价值 | — | $1.4B |
| 总资产 | — | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资EWROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | $4.2B | $100.0M | ||
| Q3 25 | $3.8B | $127.4M | ||
| Q2 25 | $4.1B | $123.0M | ||
| Q1 25 | $3.9B | $201.2M | ||
| Q4 24 | $4.0B | $89.6M | ||
| Q3 24 | $4.4B | $95.3M | ||
| Q2 24 | $2.0B | $106.7M |
总债务EWROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | — | $486.1M | ||
| Q3 25 | — | $485.7M | ||
| Q2 25 | — | $485.3M | ||
| Q1 25 | — | $485.5M | ||
| Q4 24 | — | $395.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益EWROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | $10.3B | $1.4B | ||
| Q3 25 | $10.2B | $1.5B | ||
| Q2 25 | $10.5B | $1.4B | ||
| Q1 25 | $10.1B | $1.4B | ||
| Q4 24 | $10.0B | $1.3B | ||
| Q3 24 | $9.5B | $1.3B | ||
| Q2 24 | $7.4B | $1.2B |
总资产EWROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | $13.7B | $3.1B | ||
| Q3 25 | $13.3B | $3.2B | ||
| Q2 25 | $13.5B | $3.2B | ||
| Q1 25 | $13.0B | $2.9B | ||
| Q4 24 | $13.1B | $2.8B | ||
| Q3 24 | $13.0B | $2.8B | ||
| Q2 24 | $10.1B | $2.8B |
负债/权益比EWROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $118.4M |
| 自由现金流经营现金流 - 资本支出 | — | $111.2M |
| 自由现金流率自由现金流/营收 | — | 12.3% |
| 资本支出强度资本支出/营收 | — | 0.8% |
| 现金转化率经营现金流/净利润 | — | 1.10× |
| 过去12个月自由现金流最近4个季度 | — | $621.1M |
8季度趋势，按日历期对齐
经营现金流EWROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | $450.9M | $164.7M | ||
| Q3 25 | $573.7M | $191.3M | ||
| Q2 25 | $290.2M | $175.1M | ||
| Q1 25 | $280.4M | $146.9M | ||
| Q4 24 | $-127.5M | $188.2M | ||
| Q3 24 | $351.8M | $146.9M | ||
| Q2 24 | $371.5M | $145.1M |
自由现金流EWROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | $353.5M | $159.0M | ||
| Q3 25 | $516.2M | $182.8M | ||
| Q2 25 | $240.9M | $168.0M | ||
| Q1 25 | $224.4M | $140.1M | ||
| Q4 24 | $-177.3M | $184.0M | ||
| Q3 24 | $299.9M | $139.4M | ||
| Q2 24 | $286.1M | $136.4M |
自由现金流率EWROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | 22.5% | 17.4% | ||
| Q3 25 | 33.2% | 17.8% | ||
| Q2 25 | 15.7% | 16.8% | ||
| Q1 25 | 15.9% | 17.0% | ||
| Q4 24 | -12.8% | 22.1% | ||
| Q3 24 | 22.1% | 15.2% | ||
| Q2 24 | 20.9% | 15.3% |
资本支出强度EWROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | 6.2% | 0.6% | ||
| Q3 25 | 3.7% | 0.8% | ||
| Q2 25 | 3.2% | 0.7% | ||
| Q1 25 | 4.0% | 0.8% | ||
| Q4 24 | 3.6% | 0.5% | ||
| Q3 24 | 3.8% | 0.8% | ||
| Q2 24 | 6.2% | 1.0% |
现金转化率EWROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | 4.94× | 1.41× | ||
| Q3 25 | 1.97× | 1.17× | ||
| Q2 25 | 0.87× | 1.24× | ||
| Q1 25 | 0.78× | 1.40× | ||
| Q4 24 | -0.33× | 1.78× | ||
| Q3 24 | 0.11× | 1.07× | ||
| Q2 24 | 1.01× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
